Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006187893> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2006187893 endingPage "S124" @default.
- W2006187893 startingPage "S124" @default.
- W2006187893 abstract "Material and methods: All pts receiving biologics were included in the study. Cause and length of delay/anticipation respect to scheduled administration were considered. Adherence to ADA was assessed using patient diaries. The mean duration of biological therapy was 16.5 months (1-61). Pts: 136, 60M/76F, 110CD/26UC, mean age at diagnosis 32.4 (20-73) and at 1st administration 40.5 (16-78). IFX was administered to 93/136 pts (68.4%) and ADA to 43/136 (31.6%). Indications to biologicals were: steroiddependence/resistance in 91/136 (66.9%), fistulae in 35/136 (25.8%), AZA failure in 6/136 (4.4%) others in 4/136 (2.9%). The overall number of administrations was 1763 (mean 12.9/pt, range1-73). Results: A total of 187/1763 administrations (10.6%) in 45 pts (33%) was delayed [29 IFX (32.6%), 16 ADA (43.2%) (p=0.3)]. The mean number of delayed administrations was 2.2 and the delay 13.7 days (1-35). Forgetfulness, summer holidays, pharmaceutical supply and intentional non adherence were responsible for 294 days delay (28 pts). Adverse events were responsible for 198 days delay (18 pts). A total of 82/1763 administrations (4.65%) were anticipated in 14 pts, (13 on IFX -92.8%and 1 on ADA -7.2%p<0.01), with a mean of 2.05 events/pt and an anticipation vs scheduled timing of 7.8 days (1-28). The reason for anticipation was related to practical issues in 19 (23.2%), occurrence of articular pain in 1 (1.2%) and lost response/active disease in 62 (75.6%) administrations. A clinical need and not a lack of adherence justify anticipation in these last 62 patients. Conclusions: About 30% of patients failed to adhere strictly to scheduled treatment with biologics, in 10.6% of administrations. Possible consequences of reduced compliance remain to be assessed. Interestingly, in this study lack of adherence has been found also with agents which do not require daily and/or multiple administrations. No difference has been found between IFX and ADA in terms of decreased adherence." @default.
- W2006187893 created "2016-06-24" @default.
- W2006187893 creator A5000257649 @default.
- W2006187893 creator A5007712754 @default.
- W2006187893 creator A5009322447 @default.
- W2006187893 creator A5026242246 @default.
- W2006187893 creator A5027073911 @default.
- W2006187893 creator A5035827014 @default.
- W2006187893 creator A5049412105 @default.
- W2006187893 creator A5062576007 @default.
- W2006187893 creator A5064048300 @default.
- W2006187893 creator A5067534315 @default.
- W2006187893 creator A5090002885 @default.
- W2006187893 date "2012-03-01" @default.
- W2006187893 modified "2023-10-05" @default.
- W2006187893 title "P.06.15 SAFETY OF ANTI-TNFA THERAPY IN IBD: AN ITALIAN EXPERIENCE" @default.
- W2006187893 doi "https://doi.org/10.1016/s1590-8658(12)60341-7" @default.
- W2006187893 hasPublicationYear "2012" @default.
- W2006187893 type Work @default.
- W2006187893 sameAs 2006187893 @default.
- W2006187893 citedByCount "0" @default.
- W2006187893 crossrefType "journal-article" @default.
- W2006187893 hasAuthorship W2006187893A5000257649 @default.
- W2006187893 hasAuthorship W2006187893A5007712754 @default.
- W2006187893 hasAuthorship W2006187893A5009322447 @default.
- W2006187893 hasAuthorship W2006187893A5026242246 @default.
- W2006187893 hasAuthorship W2006187893A5027073911 @default.
- W2006187893 hasAuthorship W2006187893A5035827014 @default.
- W2006187893 hasAuthorship W2006187893A5049412105 @default.
- W2006187893 hasAuthorship W2006187893A5062576007 @default.
- W2006187893 hasAuthorship W2006187893A5064048300 @default.
- W2006187893 hasAuthorship W2006187893A5067534315 @default.
- W2006187893 hasAuthorship W2006187893A5090002885 @default.
- W2006187893 hasConcept C126322002 @default.
- W2006187893 hasConcept C17991360 @default.
- W2006187893 hasConcept C71924100 @default.
- W2006187893 hasConceptScore W2006187893C126322002 @default.
- W2006187893 hasConceptScore W2006187893C17991360 @default.
- W2006187893 hasConceptScore W2006187893C71924100 @default.
- W2006187893 hasLocation W20061878931 @default.
- W2006187893 hasOpenAccess W2006187893 @default.
- W2006187893 hasPrimaryLocation W20061878931 @default.
- W2006187893 hasRelatedWork W1506200166 @default.
- W2006187893 hasRelatedWork W1977918131 @default.
- W2006187893 hasRelatedWork W1990717759 @default.
- W2006187893 hasRelatedWork W1995515455 @default.
- W2006187893 hasRelatedWork W2080531066 @default.
- W2006187893 hasRelatedWork W2748952813 @default.
- W2006187893 hasRelatedWork W2899084033 @default.
- W2006187893 hasRelatedWork W3031052312 @default.
- W2006187893 hasRelatedWork W3032375762 @default.
- W2006187893 hasRelatedWork W3108674512 @default.
- W2006187893 hasVolume "44" @default.
- W2006187893 isParatext "false" @default.
- W2006187893 isRetracted "false" @default.
- W2006187893 magId "2006187893" @default.
- W2006187893 workType "article" @default.